SCHEMBL9948370

SCHEMBL9948370

c1ccc2c(c1)Cc1cc3c(cc1C2)Cc1ncccc1C3

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
DRD1 P21728 5/20 0.35
CYP1A2 P05177 3/20 0.35
DRD3 P35462 3/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
HTR2C P28335 2/20 0.35
HRH1 P35367 2/20 0.35
CHRM2 P08172 1/20 0.35
HTR1A P08908 1/20 0.35
ADRA2A P08913 1/20 0.35
CYP2D6 P10635 1/20 0.35
CHRM1 P11229 1/20 0.35
TSHR P16473 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35
HTR2A P28223 1/20 0.35
HTR7 P34969 1/20 0.35
ADRA1A P35348 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21479447 0.94 ALOX15 (0.40) ALOX15HSD17B10DRD1CYP1A2DRD3
SCHEMBL7424121 0.87
SCHEMBL9948344 0.86 CCR1 (0.41) DRD1CYP1A2DRD3CYP2C9CYP2C19
SCHEMBL27027264 0.83 ALDH1A1 (0.46) CYP1A2CYP2C9CYP2C19CHRM2CYP2D6
SCHEMBL27027261 0.83 ALDH1A1 (0.46) CYP1A2CYP2C9CYP2C19CHRM2CYP2D6
SCHEMBL7255805 0.81 CYP2A6 (0.45) DRD1CYP1A2DRD3HTR2CHRH1
SCHEMBL4228551 0.79 CYP2A6 (0.43) ALOX15HSD17B10DRD1CYP1A2DRD3
Formic Acid SCHEMBL27997365 0.75 TRIM24 (0.39) ALOX15DRD3TSHRDRD2CYP3A4
SCHEMBL9947860 0.74 CYP1A2 (0.37) ALOX15HSD17B10DRD1CYP1A2DRD3
SCHEMBL30011414 0.72 METAP2 (0.46) CYP1A2DRD3CYP2C9CYP2C19HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8334384-B2 Process for preparing tetrahydrotetraazapentacenes and derivatives XEROX CORPORATION (US) 2012-12-18 US disclosed
US-8283659-B2 Tetrahydrotetraazapentacenes in thin-film transistors XEROX CORPORATION (US) 2012-10-09 US disclosed
US-20120161108-A1 TETRAHYDROTETRAAZAPENTACENES IN THIN-FILM TRANSISTORS XEROX CORPORATION (US) 2012-06-28 US disclosed
US-20120165529-A1 PROCESS FOR PREPARING TETRAHYDROTETRAAZAPENTACENES AND DERIVATIVES XEROX CORPORATION (US) 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120161108-A1 TETRAHYDROTETRAAZAPENTACENES IN THIN-FILM TRANSISTORS CYP4Z1, TCF4, TERT ALOX15 847/4885HSD17B10 1829/4885DRD1 1465/4885
US-20120165529-A1 PROCESS FOR PREPARING TETRAHYDROTETRAAZAPENTACENES AND DERIVATIVES DHPS, TBXA2R, DHRS9 ALOX15 1198/4885HSD17B10 283/4885DRD1 255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.